摘要
目的对小儿支原体肺炎使用阿奇霉素治疗的临床效果展开分析和探讨。方法随机选取2022年12月—2023年3月福建省将乐县总医院60例小儿支原体肺炎患儿为研究对象,按照随机数表法划分为对照组30例和观察组30例,两组常规治疗方法一致,对照组配合红霉素治疗,观察组配合阿奇霉素治疗,针对两组疗效展开比较。结果治疗后,观察组患儿白介素-6、C反应蛋白、降钙素原测定结果均低于对照组,差异有统计学意义(P<0.05)。观察组患儿肺部啰音、喘息、咳嗽、发热改善情况统计结果均优于对照组,差异有统计学意义(P<0.05);观察组肺部阴影吸收率(96.67%)高于对照组(73.33%),差异有统计学意义(χ^(2)=4.705,P<0.05);观察组患儿临床总疗效(93.33%)高于对照组(70.00%),差异有统计学意义(χ^(2)=5.454,P<0.05);观察组不良反应发生率(0)低于对照组(13.33%),差异有统计学意义(χ^(2)=4.285,P<0.05)。结论阿奇霉素治疗小儿支原体肺炎患儿,降低炎症因子指标,患儿临床症状消失时间更短,临床疗效更高,不良反应更低,因此具有更高治疗安全性。
Objective To analyze and discuss the clinical effect of azithromycin in the treatment of mycoplasma pneumonia in children.Methods 60 children with mycoplasma pneumonia in children admitted to Jiangle County General Hospital of Fujian Province from December 2022 to March 2023 were randomly selected as study objects.According to the random number table method,they were divided into the control group of 30 cases and the observation group of 30 cases.The conventional treatment methods of the two groups were the same.The control group was treated with erythromycin,and the observation group was treated with azithromycin.The efficacy of the two groups was compared.Results After treatment,the measurement results of interleukin-6,C-reactive protein,and procalcitonin in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The statistical results of improvements in pulmonary rales,wheezing,cough and fever in the observation group were all better than those in the control group,and the difference was statistically significant(P<0.05).The lung shadow absorption rate of the observation group(96.67%)was higher than that of the control group(73.33%),and the difference was statistically significant(χ^(2)=4.705,P<0.05).The total clinical efficacy of the observation group of children(93.33%)was higher than that of the control group(70.00%),and the difference was statistically significant(χ^(2)=5.454,P<0.05).The incidence rate of adverse reactions in the observation group(0)was lower than that in the control group(13.33%),and the difference was statistically significant(χ^(2)=4.285,P<0.05).Conclusion Using azithromycin to treat children with mycoplasma pneumonia can reduce inflammatory factor indicators,shorten the time for the clinical symptoms to disappear,have higher clinical efficacy and lower adverse reactions.Therefore,it has higher treatment safety.
作者
苏晓阳
SU Xiaoyang(Department of Pediatrics,Jiangle County General Hospital,Sanming,Fujian Province,353300 China)
出处
《中外医疗》
2023年第24期102-105,111,共5页
China & Foreign Medical Treatment
关键词
小儿支原体肺炎
阿奇霉素
临床疗效
不良反应
炎症因子
红霉素
Mycoplasma pneumonia in children
Azithromycin
Clinical efficacy
Adverse reactions
Inflammatory factors
Erythromycin
